Zone 1 미숙아망막병증에서 레이저 광응고술과 유리체강내 베바시주맙 주입술의 효과

Effect of Laser Photocoagulation and Intravitreal Bevacizumab Injection on Zone I Retinopathy of Prematurity

Purpose: To evaluate the efficacy and safety of laser photocoagulation and intravitreal injection of bevacizumab in zone I ROP (retinopathy of prematurity) accompanied with plus signs. Methods: We performed a retrospective analysis of the records of 12 eyes of 7 premature infants with zone I ROP accompanied with plus signs, treated with diode laser photocoagulation and intravitreal injection of bevacizumab that were followed- up for at least 12 months. Results: Mean gestational age was 30 + 2 weeks, mean birth weight was 1437 ± 478 g, mean follow-up period was 14.7 ± 2.0 months and mean age of diagnosis was 36 + 3 weeks. Plus signs were disappeared after an average of 10.1 ± 2.4 postoperative days in all 12 eyes. The outcome was favorable in 11 (91.7%) of 12 treated eyes after a minimum of 12 months of follow-up. No local or systemic complications were observed. Conclusions: Laser photocoagulation and intravitreal injection of bevacizumab are effective and safe for treatment of zone I ROP accompanied with plus signs and require long-term follow-up. J Korean Ophthalmol Soc 2012;53(1):120-126